利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.024 秒)

    Agents for Suppressing the Induction of Cytotoxic T Cells
    1.
    发明申请
    Agents for Suppressing the Induction of Cytotoxic T Cells 有权
    抑制细胞毒性T细胞诱导剂

    公开(公告)号：US20090263384A1

    公开(公告)日：2009-10-22

    申请号：US12085065

    申请日：2006-11-15

    申请人： Masaji Okada ,  Masafumi Takahashi ,  Atsushi Izawa ,  Yoshiyuki Ohsugi ,  Masahiko Mihara

    发明人： Masaji Okada ,  Masafumi Takahashi ,  Atsushi Izawa ,  Yoshiyuki Ohsugi ,  Masahiko Mihara

    IPC分类号： A61K39/395 ,  A61P37/06

    CPC分类号： C07K16/248 ,  A61K2039/505 ,  C07K16/2866

    摘要： The effect of anti-IL-6 receptor antibodies in suppressing cytotoxic T cell induction was examined. The results showed that CTL activity against alloantigens was statistically significantly reduced in mice treated with anti-IL-6 receptor antibodies as compared to mice not treated with antibodies and mice treated with a control antibody. The anti-IL-6 receptor antibody was also administered to recipients of a mouse model for allogenic heart transplantation. As a result, histopathological findings showed that inflammatory cell infiltration into transplanted hearts was suppressed and the survival period of transplanted hearts was significantly prolonged. Thus, the present inventors for the first time discovered that administration of anti-IL-6 receptor antibodies could suppress cytotoxic T cell induction and thereby suppress acute rejection after transplantation.

    摘要翻译： 检测抗IL-6受体抗体在抑制细胞毒T细胞诱导中的作用。 结果表明，与未用抗体治疗的小鼠相比，用对照抗体处理的小鼠相比，用抗IL-6受体抗体处理的小鼠中，抗同种异体抗体的CTL活性显着降低。 还将抗IL-6受体抗体施用于用于同种异体心脏移植的小鼠模型的受体。 结果，组织病理学检查结果显示，移植心脏的炎症细胞浸润被抑制，移植心脏的存活期显着延长。 因此，本发明人首次发现，抗IL-6受体抗体的施用可以抑制细胞毒性T细胞诱导，从而抑制移植后的急性排斥反应。

    Pharmaceutical agents containing methotrexate derivative
    10.
    发明授权
    Pharmaceutical agents containing methotrexate derivative 失效
    含甲氨蝶呤衍生物的药剂

    公开(公告)号：US5958928A

    公开(公告)日：1999-09-28

    申请号：US913967

    申请日：1997-09-25

    申请人： Masahiko Mihara

    发明人： Masahiko Mihara

    IPC分类号： A61K31/519 ,  A61K31/5415 ,  C07D475/08 ,  A61K31/505

    CPC分类号： A61K31/519 ,  A61K31/5415 ,  C07D475/08

    摘要： Compounds represented by the general formula: ##STR1## (where R.sub.1 is one member selected from the group consisting of CH.sub.2, CH.sub.2 CH.sub.2, CH.sub.2 O, CH.sub.2 S and CH.sub.2 SO; R.sub.2 is a hydrogen atom or a lower alkyl group having 1-4 carbon atoms or a benzyl group; R.sub.3 is a group represented by the general formula COOR.sub.4, the general formula NHCOR.sub.5, the general formula CONR.sub.6 R.sub.7, PO.sub.3 H.sub.2 or SO.sub.3 H; and n is an integer of 1-4) or salts therof are useful as therapeutic agents of autoimmune diseases such as systemic lupus erythematosus and nephritic diseases such as glomerulonephritis.

    摘要翻译： PCT No.PCT / JP96 / 00780 Sec。 371日期：1997年9月25日 102（e）1997年9月25日PCT 1996年3月26日PCT公布。 第WO96 / 30019号公报 日期：1996年10月3日由以下通式表示的化合物：（其中R 1为选自CH 2，CH 2 CH 2，CH 2 O，CH 2 S和CH 2 SO 2中的一个; R 2为氢原子或具有1-4个碳原子的低级烷基 或苄基; R 3是由通式COOR 4，通式NHCOR 5，通式CONR 6 R 7，PO 3 H 2或SO 3 H表示的基团，n是1-4的整数）或其可用作自身免疫的治疗剂 疾病如系统性红斑狼疮和肾炎如肾小球性肾炎。